Joshua Patterson

Geen lopende functies

Vermogen: 10 155 $ op 31-03-2024

48 jaar

Health Technology

Consumer Services

Eerdere bekende functies van Joshua Patterson

Bedrijven	Functie	Begin	Einde
GAMIDA CELL LTD.	Compliance Officer	01-08-2021	26-04-2024
GAMIDA CELL LTD.	General Counsel	01-08-2021	26-04-2024
IONIS PHARMACEUTICALS, INC.	Director/Board Member	01-12-2006	01-03-2018
IONIS PHARMACEUTICALS, INC.	Corporate Officer/Principal	01-12-2006	01-03-2018
Amylin Pharmaceuticals, Inc. Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA.	Corporate Officer/Principal	01-10-2000	01-09-2006
AKCEA THERAPEUTICS, INC.	General Counsel	01-03-2018	-
AKCEA THERAPEUTICS, INC.	Corporate Secretary	01-03-2018	11-03-2020

Carthage College	Undergraduate Degree
Syracuse University	Graduate Degree

Internationaal

Verenigde Staten

Operationeel

General Counsel	2
Corporate Officer/Principal	2
Corporate Secretary	1

Sectoraal

Health Technology	5
Consumer Services	3

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	2
IONIS PHARMACEUTICALS, INC.	Health Technology
GAMIDA CELL LTD.	Health Technology

Bedrijven in privébezit	2
Amylin Pharmaceuticals, Inc. Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA.	Health Technology
Akcea Therapeutics, Inc. Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.	Health Technology

Bedrijven in privébezit

Health Technology